Evidence map›Paper›PMID 24787143›Full record

Trial reportThe international journal of neuropsychopharmacology2014

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.

Roger S McIntyre, Søren Lophaven, Christina K Olsen

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The international journal of neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03432221 (Efficacy Of Switching From SSRI to Desvenlafaxine on Cognitive Function In Patients With an Acute Episode of Major Depression), which is not on this map. Cited by 156 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
156citing papers in PubMed, 14 pooled it
46.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03432221 unknown statusnot on this mapstarted 2018, after this paper: background citation

Efficacy Of Switching From SSRI to Desvenlafaxine on Cognitive Function In Patients With an Acute Episode of Major Depression

TypeobservationalSponsorCorporacion Parc TauliRan2018 to 2019Enrolled36ConditionsMajor Depressive DisorderArmsDesvenlafaxine
3 · Its place in the literature

Who cites it

156 citing papers in PubMed, 14 syntheses or guidelines pooled it, 424 citations in OpenAlex.

  1. Guideline
  2. Use of vortioxetine in different neurological fields: a systematic review and future perspectives.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Vortioxetine for depression in adults.The Cochrane database of systematic reviews · 2017
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Early efficacy of rTMS intervention at week 2 predicts subsequent responses at week 24 in schizophrenia in a randomized controlled trial.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Trial
  16. 5-HTBiological psychiatry. Cognitive neuroscience and neuroimaging · 2023
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

96 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Roger S McIntyreMood Disorders Psychopharmacology Unit,University Health Network, University of Toronto,Toronto, ON,Canada.
Søren LophavenH. Lundbeck A/S,Copenhagen,Denmark.
Christina K OlsenH. Lundbeck A/S,Copenhagen,Denmark.
Lundbeck (Denmark) · DKUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of vortioxetine 10 and 20 mg/d vs. placebo on cognitive function and depression in adults with recurrent moderate-to-severe major depressive disorder (MDD) was evaluated. Patients (18-65 yr, N = 602) were randomized (1:1:1) to vortioxetine 10 or 20 mg/d or placebo for 8 wk in a double-blind multi-national study. Cognitive function was assessed with objective neuropsychological tests of executive function, processing speed, attention and learning and memory, and a subjective cognitive measure. The primary outcome measure was change from baseline to week 8 in a composite z-score comprising the Digit Symbol Substitution Test (DSST) and Rey Auditory Verbal Learning Test (RAVLT) scores. Depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). In the pre-defined primary efficacy analysis, both doses of vortioxetine were significantly better than placebo, with mean treatment differences vs. placebo of 0.36 (vortioxetine 10 mg, p < 0.0001) and 0.33 (vortioxetine 20 mg, p < 0.0001) on the composite cognition score. Significant improvement vs. placebo was observed for vortioxetine on most of the secondary objectives and subjective patient-reported cognitive measures. The differences to placebo in the MADRS total score at week 8 were -4.7 (10 mg: p < 0.0001) and -6.7 (20 mg: p < 0.0001). Path and subgroup analyses indicate that the beneficial effect of vortioxetine on cognition is largely a direct treatment effect. No safety concern emerged with vortioxetine. Vortioxetine significantly improved objective and subjective measures of cognitive function in adults with recurrent MDD and these effects were largely independent of its effect on improving depressive symptoms.

Indexed as

AdolescentAdultAgedAnalysis of VarianceAnti-Anxiety AgentsCognition DisordersDepressionDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansInternational CooperationMaleMiddle AgedNeuropsychological TestsPiperazinesAnti-Anxiety AgentsPiperazinesSulfidesVortioxetine

Identifiers

PMID24787143
PMCPMC4162519
OpenAlexW2153644230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.